ROVI Stock Overview
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €83.30 |
| 52 Week High | €83.30 |
| 52 Week Low | €38.38 |
| Beta | 0.49 |
| 1 Month Change | 4.58% |
| 3 Month Change | 28.55% |
| 1 Year Change | 105.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 128.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROVI | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 4.2% | 1.9% | -0.08% |
| 1Y | 105.9% | 8.7% | 2.6% |
Return vs Industry: ROVI exceeded the Austrian Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: ROVI exceeded the Austrian Market which returned 2.6% over the past year.
Price Volatility
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: ROVI has not had significant price volatility in the past 3 months.
Volatility Over Time: ROVI's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,925 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| ROVI fundamental statistics | |
|---|---|
| Market cap | €4.40b |
| Earnings (TTM) | €170.34m |
| Revenue (TTM) | €829.51m |
25.9x
P/E Ratio5.3x
P/S RatioIs ROVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROVI income statement (TTM) | |
|---|---|
| Revenue | €829.51m |
| Cost of Revenue | €337.22m |
| Gross Profit | €492.29m |
| Other Expenses | €321.95m |
| Earnings | €170.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 3.29 |
| Gross Margin | 59.35% |
| Net Profit Margin | 20.53% |
| Debt/Equity Ratio | 12.0% |
How did ROVI perform over the long term?
See historical performance and comparison